Market Place
Sourcing Support
Bluejay Unveils First Preclinical Data for MASH Drug BJT-188
07 May 2025 //
GLOBENEWSWIRE
Bluejay Therapeutics to Present Preclinical Data at EASL Congress
23 Apr 2025 //
GLOBENEWSWIRE
Bluejay Therapeutics Starts AZURE-1 Trial for Hepatitis D
26 Mar 2025 //
GLOBENEWSWIRE
Bluejay Therapeutics Appoints Mary Cromwell As SVP, Technical Ops
12 Feb 2025 //
GLOBENEWSWIRE
Bluejay’s Brelovitug Get FDA Breakthrough For Hepatitis Delta
21 Jan 2025 //
GLOBENEWSWIRE
Bluejay to Present at 43rd J.P. Morgan Healthcare Conference
19 Dec 2024 //
GLOBENEWSWIRE
Bluejay Therapeutics Announces Expansion of Leadership Team & BOD
21 Nov 2024 //
GLOBENEWSWIRE
Bluejay’s BJT-778 Achieves 100% Response in Chronic Hepatitis D
15 Nov 2024 //
GLOBENEWSWIRE
Bluejay Announces Data In Chronic Hepatitis D And B At AASLD
16 Oct 2024 //
BUSINESSWIRE
Bluejay touts positive data for chronic hepatitis D treatment
05 Jun 2024 //
PHARMACEUTICAL TECHNOLOGY
Bluejay: Positive Phase 2 BJT-778 Data In Chronic Hepatitis D At EASL
05 Jun 2024 //
GLOBENEWSWIRE
Bluejay Gets EMA Orphan Opinion For BJT-778 In Chronic Hepatitis D
29 May 2024 //
GLOBENEWSWIRE
Bluejay To Present At EASL 2024
22 May 2024 //
GLOBENEWSWIRE
Bluejay $182M Series C To Propel Clinical Pipeline
09 May 2024 //
GLOBENEWSWIRE
Bluejay Receipt of PRIME Designation from(EMA) for BJT-778
25 Mar 2024 //
GLOBENEWSWIRE
Exicure and Bluejay Therapeutics Inc. Enter into a Patent License Agreement
05 Feb 2024 //
BUSINESSWIRE
Bluejay Therapeutics expands management team
21 Sep 2023 //
GLOBENEWSWIRE
Bluejay Therapeutics Advances in Hepatitis B and D Trials
01 Jun 2023 //
GLOBENEWSWIRE
Bluejay Received Regulatory Clearance to Initiate Clinical Studies of BJT-778
01 Dec 2022 //
GLOBENEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.